462 related articles for article (PubMed ID: 29047372)
21. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
Fass AD; Gershman JA
Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Kidney Transplant Recipients with Post-transplant Diabetes Mellitus (PTDM)- a Systematic Review and Meta-Analysis.
Abdelaziz TS; Ali AY; Fatthy M
Curr Diabetes Rev; 2020; 16(6):580-585. PubMed ID: 30907326
[TBL] [Abstract][Full Text] [Related]
23. Alogliptin benzoate for management of type 2 diabetes.
Saisho Y
Vasc Health Risk Manag; 2015; 11():229-43. PubMed ID: 25914541
[TBL] [Abstract][Full Text] [Related]
24. Thiazides in the management of hypertension in older adults - a systematic review.
Sommerauer C; Kaushik N; Woodham A; Renom-Guiteras A; Martinez YV; Reeves D; Kunnamo I; Al Qur An T; Hübner S; Sönnichsen A
BMC Geriatr; 2017 Oct; 17(Suppl 1):228. PubMed ID: 29047359
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
[TBL] [Abstract][Full Text] [Related]
26. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
[TBL] [Abstract][Full Text] [Related]
27. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety.
Deacon CF; Holst JJ
Expert Opin Pharmacother; 2013 Oct; 14(15):2047-58. PubMed ID: 23919507
[TBL] [Abstract][Full Text] [Related]
28. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
Bonora E; Cigolini M
Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
[TBL] [Abstract][Full Text] [Related]
29. The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes.
Stoian AP; Sachinidis A; Stoica RA; Nikolic D; Patti AM; Rizvi AA
Metabolism; 2020 Aug; 109():154295. PubMed ID: 32553739
[TBL] [Abstract][Full Text] [Related]
30. Polypharmacy in chronic diseases-Reduction of Inappropriate Medication and Adverse drug events in older populations by electronic Decision Support (PRIMA-eDS): study protocol for a randomized controlled trial.
Sönnichsen A; Trampisch US; Rieckert A; Piccoliori G; Vögele A; Flamm M; Johansson T; Esmail A; Reeves D; Löffler C; Höck J; Klaassen-Mielke R; Trampisch HJ; Kunnamo I
Trials; 2016 Jan; 17():57. PubMed ID: 26822311
[TBL] [Abstract][Full Text] [Related]
31. Dipeptidyl peptidase-4 inhibitors and risk of arthralgia: A systematic review and meta-analysis.
Men P; He N; Song C; Zhai S
Diabetes Metab; 2017 Dec; 43(6):493-500. PubMed ID: 28778563
[TBL] [Abstract][Full Text] [Related]
32. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
Cornell S
J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
[TBL] [Abstract][Full Text] [Related]
33. [Research progress of mechanisms through which dipeptidyl peptidase-4 inhibitors regulate glycemia].
Wang JS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Apr; 35(2):229-33. PubMed ID: 23643015
[TBL] [Abstract][Full Text] [Related]
34. Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor-α concentrations: A systematic review and meta-analysis of controlled trials.
Atkin SL; Katsiki N; Banach M; Mikhailidis DP; Pirro M; Sahebkar A
J Diabetes Complications; 2017 Sep; 31(9):1458-1464. PubMed ID: 28647512
[TBL] [Abstract][Full Text] [Related]
35. The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Luo Y; Lu K; Liu G; Wang J; Laurent I; Zhou X
Clin Drug Investig; 2018 Dec; 38(12):1089-1108. PubMed ID: 30255388
[TBL] [Abstract][Full Text] [Related]
36. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
37. Clinical inertia among patients with type 2 diabetes mellitus treated with DPP-4i and/or SGLT-2i.
Lanzinger S; Schmid SM; Welp R; Zimmermann A; Fasching P; Wagner S; Holl RW
Diabetes Res Clin Pract; 2018 Dec; 146():162-171. PubMed ID: 30367902
[TBL] [Abstract][Full Text] [Related]
38. DPP IV inhibitors: successes, failures and future prospects.
Kshirsagar AD; Aggarwal AS; Harle UN; Deshpande AD
Diabetes Metab Syndr; 2011; 5(2):105-12. PubMed ID: 22813415
[TBL] [Abstract][Full Text] [Related]
39. A systematic review of the benefits and harms of dipeptidyl peptidase-4 inhibitor for chronic kidney disease.
Kamiya H
Hemodial Int; 2017 Jan; 21(1):72-83. PubMed ID: 27436163
[TBL] [Abstract][Full Text] [Related]
40. Plant dipeptidyl peptidase-IV inhibitors as antidiabetic agents: a brief review.
Turdu G; Gao H; Jiang Y; Kabas M
Future Med Chem; 2018 May; 10(10):1229-1239. PubMed ID: 29749760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
